EAS 2026 at a glance
EAS 2026 in Athens will test whether lipid innovation is moving from LDL-C reduction alone toward modality choice, patient identification, and workflow execution.
The conference highlights emerging lipid-lowering therapies, PCSK9 treatment strategies, ApoC-III and ANGPTL3 targeting, residual cardiovascular risk, and the growing role of artificial intelligence in lipid management. These developments could influence treatment positioning, cardiovascular prevention and clinical decision-making.
📅 Build your schedule around the topics that matter most.
📥 Download the EAS 2026_Preview_by_LucidQuest
EAS 2026: Key Developments in Lipid Management
PCSK9 Modality Trade-offs
VERVE-102, enlicitide, STX-1150, evolocumab, lerodalcibep, and inclisiran will sharpen questions around route, durability, reversibility, and adherence.
ApoC-III and ANGPTL3 Positioning
Olezarsen, plozasiran, and AZD1705 will test whether severe TG strategies stay focused on pancreatitis risk or expand into ASCVD residual risk.
Residual Inflammation
Ruvonoflast and inflammation-focused sessions may re-open the question of whether inflammatory-risk biology can define a treatable ASCVD subgroup.
Oral LDL-C Intensification
Daiichi Sankyo Europe GmbH and MENARINI Group will position oral combinations and CETP inhibition against injectable, RNA-based, and durable PCSK9 approaches.
EAS 2026: Competitor and Industry Signals
Novartis and Eli Lilly: Lp(a) Screening and Treatment Readiness
Lp(a) sessions will focus on risk stratification and testing infrastructure ahead of dedicated Lp(a)-lowering launch readiness.
Chiesi: Homozygous Familial Hypercholesterolemia
HoFH remains a rare-disease proving ground for LDL-C depth, pediatric applicability, real-world durability, and apheresis reduction.
MSD: Oral PCSK9 Inhibition
Enlicitide data will be important for the oral PCSK9 case beyond LDL-C alone, including ApoB effects.
Artificial Intelligence and Machine Learning at EAS 2026
AI-Enhanced Exposomics
Sessions suggest AI is being tested at actionable lipid and cardiovascular risk decision points.
NMR and Metabolomics Machine Learning
Machine learning may support lipoprotein profiling, residual-risk stratification, and trial enrichment.
Digital Lp(a) Screening
Digiphysical cascade screening could influence earlier identification, referral, and therapy prioritization.
What We Are Watching After EAS 2026
- Whether PCSK9 modalities demonstrate meaningful differentiation in durability, reversibility, safety, and adherence.
- Whether Lp(a) screening models translate into actionable testing pathways before therapy adoption scales.
- Whether apoC-III and ANGPTL3 data support positioning in severe TG or broader ASCVD residual-risk populations.
Download LucidQuest’s EAS 2026 Preview Report
Download our EAS 2026 preview report for deeper analysis of emerging lipid-lowering therapies, PCSK9 treatment strategies, cardiovascular risk management and AI applications in lipidology.
📅 Build your schedule around the sessions that matter most.
📥 Download the EAS 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
